SLAMF6 and B-cell chronic lymphocytic leukemia: On a hopeful note for combination treatments, preliminary research posits that synchronizing an anti-SLAMF6 antibody with the drug ibrutinib effectively stymies CLL cell growth, paving the way for potential CLL therapeutic avenues [30].